{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:43:18Z","timestamp":1759092198083,"version":"3.41.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Primary Children's Hospital Foundation","award":["Pharmacotherapy Subspecialty award"],"award-info":[{"award-number":["Pharmacotherapy Subspecialty award"]}]},{"name":"American Foundation for Pharmaceutical Education\u2019s Clinical Pharmaceutical Sciences Fellowship"},{"name":"Thrasher Foundation","award":["10026771-F1"],"award-info":[{"award-number":["10026771-F1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40262-015-0286-y","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T09:18:21Z","timestamp":1432027101000},"page":"1237-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy"],"prefix":"10.1007","volume":"54","author":[{"given":"Jessica K.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Beachy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana C.","family":"Baserga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Spigarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M. T.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"issue":"6","key":"286_CR1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.earlhumdev.2010.05.010","volume":"86","author":"JJ Kurinczuk","year":"2010","unstructured":"Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86(6):329\u201338.","journal-title":"Early Hum Dev."},{"issue":"4","key":"286_CR2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.clp.2012.09.008","volume":"39","author":"S Shankaran","year":"2012","unstructured":"Shankaran S. Hypoxic-ischemic encephalopathy and novel strategies for neuroprotection. Clin Perinatol. 2012;39(4):919\u201329.","journal-title":"Clin Perinatol."},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"c363","DOI":"10.1136\/bmj.c363","volume":"340","author":"AD Edwards","year":"2010","unstructured":"Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, et al. Neurological outcomes at 18\u00a0months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010;340:c363.","journal-title":"BMJ."},{"issue":"15","key":"286_CR4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMcps050929","volume":"353","author":"S Shankaran","year":"2005","unstructured":"Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574\u201384.","journal-title":"N Engl J Med."},{"key":"286_CR5","doi-asserted-by":"crossref","unstructured":"Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663\u2013670.","DOI":"10.1016\/S0140-6736(05)70932-6"},{"issue":"14","key":"286_CR6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa0900854","volume":"361","author":"DV Azzopardi","year":"2009","unstructured":"Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349\u201358.","journal-title":"N Engl J Med."},{"issue":"6","key":"286_CR7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archpediatrics.2011.1772","volume":"166","author":"MA Tagin","year":"2012","unstructured":"Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2012;166(6):558\u201366.","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"19","key":"286_CR8","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"ML Brines","year":"2000","unstructured":"Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97(19):10526\u201331.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"286_CR9","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1073\/pnas.0709715105","volume":"105","author":"C Casals-Pascual","year":"2008","unstructured":"Casals-Pascual C, Idro R, Gicheru N, Gwer S, Kitsao B, Gitau E, et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc Natl Acad Sci USA. 2008;105(7):2634\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"286_CR10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00008506-200604000-00007","volume":"18","author":"M Hasselblatt","year":"2006","unstructured":"Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006;18(2):132\u20138.","journal-title":"J Neurosurg Anesthesiol."},{"issue":"1\u20132","key":"286_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-3806(00)00118-8","volume":"125","author":"C Dame","year":"2000","unstructured":"Dame C, Bartmann P, Wolber E, Fahnenstich H, Hofmann D, Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res. 2000;125(1\u20132):69\u201374.","journal-title":"Brain Res Dev Brain Res."},{"issue":"1","key":"286_CR12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/00006450-199801000-00007","volume":"43","author":"SE Juul","year":"1998","unstructured":"Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43(1):40\u20139.","journal-title":"Pediatr Res."},{"issue":"1\u20133","key":"286_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2004.10.035","volume":"505","author":"WA Banks","year":"2004","unstructured":"Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol. 2004;505(1\u20133):93\u2013101.","journal-title":"Eur J Pharmacol."},{"key":"286_CR14","doi-asserted-by":"crossref","unstructured":"Grasso G, Graziano F, Sfacteria A, Carletti F, Meli F, Maugeri R, et al. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery. 2009;65(4):763\u2013769 (discussion 769\u201370).","DOI":"10.1227\/01.NEU.0000347475.73347.5F"},{"issue":"2","key":"286_CR15","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1542\/peds.2008-3553","volume":"124","author":"C Zhu","year":"2009","unstructured":"Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2):e218\u201326.","journal-title":"Pediatrics."},{"issue":"5","key":"286_CR16","doi-asserted-by":"crossref","first-page":"e1135","DOI":"10.1542\/peds.2009-2268","volume":"125","author":"H Elmahdy","year":"2010","unstructured":"Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010;125(5):e1135\u201342.","journal-title":"Pediatrics."},{"issue":"4","key":"286_CR17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1542\/peds.2012-0498","volume":"130","author":"YW Wu","year":"2012","unstructured":"Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012;130(4):683\u201391.","journal-title":"Pediatrics."},{"issue":"4","key":"286_CR18","first-page":"375","volume":"20","author":"IC Macdougall","year":"2000","unstructured":"Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000;20(4):375\u201381.","journal-title":"Semin Nephrol."},{"key":"286_CR19","doi-asserted-by":"crossref","unstructured":"Ibbotson T, Goa KL. Darbepoetin alfa. Drugs. 2001;61(14):2097\u20132104 (discussion 105\u2013106).","DOI":"10.2165\/00003495-200161140-00007"},{"issue":"Suppl 1","key":"286_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","volume":"84","author":"JC Egrie","year":"2001","unstructured":"Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl 1):3\u201310.","journal-title":"Br J Cancer."},{"issue":"2","key":"286_CR21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1124\/jpet.110.176602","volume":"337","author":"L Cherian","year":"2011","unstructured":"Cherian L, Goodman JC, Robertson C. Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats. J Pharmacol Exp Ther. 2011;337(2):451\u20136.","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"286_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.jp.7211498","volume":"26","author":"TL Warwood","year":"2006","unstructured":"Warwood TL, Ohls RK, Lambert DK, Jones C, Scoffield SH, Gupta N, et al. Intravenous administration of darbepoetin to NICU patients. J Perinatol. 2006;26(5):296\u2013300.","journal-title":"J Perinatol."},{"issue":"11","key":"286_CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.jp.7211387","volume":"25","author":"TL Warwood","year":"2005","unstructured":"Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol. 2005;25(11):725\u201330.","journal-title":"J Perinatol."},{"key":"286_CR24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","volume":"49","author":"E Kuhn","year":"2005","unstructured":"Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020\u201338.","journal-title":"Comput Stat Data Anal."},{"issue":"12","key":"286_CR25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","volume":"165","author":"BJ Anderson","year":"2006","unstructured":"Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819\u201329.","journal-title":"Eur J Pediatr."},{"issue":"2","key":"286_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. Aaps J. 2011;13(2):143\u201351.","journal-title":"Aaps J."},{"issue":"2","key":"286_CR27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-3565(24)29444-1","volume":"298","author":"S Chapel","year":"2001","unstructured":"Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298(2):820\u20134.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"286_CR28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0301-472X(01)00614-2","volume":"29","author":"SH Chapel","year":"2001","unstructured":"Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol. 2001;29(4):425\u201331.","journal-title":"Exp Hematol."},{"issue":"9","key":"286_CR29","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11095-007-9295-3","volume":"24","author":"KJ Freise","year":"2007","unstructured":"Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy. Pharm Res. 2007;24(9):1653\u20139.","journal-title":"Pharm Res."},{"key":"286_CR30","doi-asserted-by":"crossref","unstructured":"Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol. 2002;69(5\u20136):265\u201374.","DOI":"10.1034\/j.1600-0609.2002.02813.x"},{"issue":"1","key":"286_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3181\/00379727-100-24516","volume":"100","author":"F Stohlman Jr","year":"1959","unstructured":"Stohlman F Jr, Brecher G. Humoral regulation of erythropoiesis: V. Relationship of plasma erythropoietine level to bone marrow activity. Proc Soc Exp Biol Med. 1959;100(1):40\u20133.","journal-title":"Proc Soc Exp Biol Med."},{"issue":"6","key":"286_CR32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.clpt.6100165","volume":"81","author":"JA Widness","year":"2007","unstructured":"Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 2007;81(6):873\u20139.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"286_CR33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-3565(25)11173-7","volume":"261","author":"JA Widness","year":"1992","unstructured":"Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH. Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Ther. 1992;261(3):977\u201384.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"286_CR34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2125.2006.02756.x","volume":"63","author":"H Takama","year":"2007","unstructured":"Takama H, Tanaka H, Nakashima D, Ogata H, Uchida E, Akizawa T, et al. Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration. Br J Clin Pharmacol. 2007;63(3):300\u20139.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"286_CR35","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1208\/aapsj080364","volume":"8","author":"B Agoram","year":"2006","unstructured":"Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J. 2006;8(3):E552\u201363.","journal-title":"AAPS J."},{"issue":"1","key":"286_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2125.2006.02752.x","volume":"63","author":"B Agoram","year":"2007","unstructured":"Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol. 2007;63(1):41\u201352.","journal-title":"Br J Clin Pharmacol."},{"key":"286_CR37","doi-asserted-by":"crossref","unstructured":"Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, Bauer C. Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol (1985). 1989;66(4):1785\u20138.","DOI":"10.1152\/jappl.1989.66.4.1785"},{"issue":"11","key":"286_CR38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00467-002-0932-0","volume":"17","author":"G Lerner","year":"2002","unstructured":"Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002;17(11):933\u20137.","journal-title":"Pediatr Nephrol."},{"issue":"12","key":"286_CR39","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0286-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0286-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T01:06:31Z","timestamp":1748394391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0286-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0286-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}